scispace - formally typeset
M

Michael G. Chez

Researcher at Rosalind Franklin University of Medicine and Science

Publications -  18
Citations -  1710

Michael G. Chez is an academic researcher from Rosalind Franklin University of Medicine and Science. The author has contributed to research in topics: Autism & Epilepsy. The author has an hindex of 13, co-authored 16 publications receiving 1625 citations. Previous affiliations of Michael G. Chez include Washington University in St. Louis & Rush University Medical Center.

Papers
More filters
Journal ArticleDOI

Elevation of tumor necrosis factor-alpha in cerebrospinal fluid of autistic children.

TL;DR: Elevation of cerebrospinal fluid levels of tumor necrosis factor-alpha was significantly higher than concurrent serum levels in all of the patients studied and may offer a unique insight into central nervous system inflammatory mechanisms that may contribute to the onset of autism.
Journal ArticleDOI

Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders

TL;DR: Children with LKSV and ASD have a greater frequency of serum antibodies to brain endothelial cells and to nuclei than children with NNIs or healthy children, which raises the possibility that autoimmunity plays a role in the pathogenesis of language and social developmental abnormalities in a subset of children with these disorders.
Journal ArticleDOI

Frequency of epileptiform EEG abnormalities in a sequential screening of autistic patients with no known clinical epilepsy from 1996 to 2005.

TL;DR: A retrospective review of 24-hour ambulatory digital EEG data collected from 889 ASD patients presenting between 1996 and 2005 shows that 540 of 889 subjects had abnormal EEG epileptiform activity in sleep with no difference based on clinical regression.
Journal ArticleDOI

Memantine as adjunctive therapy in children diagnosed with autistic spectrum disorders: an observation of initial clinical response and maintenance tolerability.

TL;DR: In this article, open-label add-on therapy was offered to 151 patients with prior diagnoses of autism or Pervasive Developmental Disorder Not Otherwise Specified over a 21-month period.